Evidence map›Paper›PMID 39727015›Full record

ArticleCancer research and treatment2025

Clinical Impact of TP53 Mutations in Patients with Head and Neck Cancer Who Were Treated with Targeted Therapies or Immunotherapy.

Eun Joo Kang, Shinwon Hwang, Yun-Gyoo Lee, Jong-Kwon Choi, Seong Hoon Shin, Yoon Hee Choi, Keun-Wook Lee, Hyun Woo Lee, Min Kyoung Kim, Seung Taek Lim and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Eun Joo KangDivision of Hemato-oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Shinwon HwangDepartment of Dermatology, Yonsei University College of Medicine, Seoul, Korea.
Yun-Gyoo LeeDepartment of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jong-Kwon ChoiDivision of Hematology and Medical Oncology, Department of Internal Medicine, Konyang University Hospital, Daejeon, Korea.
Seong Hoon ShinDepartment of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
Yoon Hee ChoiDivision of Hematology-Oncology, Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
Keun-Wook LeeDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Hyun Woo LeeDepartment of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
Min Kyoung KimDivision of Hematology-Oncology, Department of Internal Medicine, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea.
Seung Taek LimDepartment of Hematology and Medical Oncology, Wonju Severance Christianity Hospital, Wonju, Korea.
Hwan Jung YunDepartment of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Sang-Gon ParkDepartment of Hemato-oncology, Chosun University Hospital, Gwangju, Korea.
Sangwoo KimDepartment of Biomedical Systems Informatics and Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Sung-Bae KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hye Ryun KimDivison of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

Funding

Ministry of Health and Welfare HA16C0015Ministry of Science and ICTNational Research Foundation of Korea RS-2023-00261820
6 · The paper itself

Abstract

purposeTumor suppressor p53 (TP53) mutations are common in head and neck squamous cell carcinoma (HNSCC). We evaluated their clinical impact in patients treated with targeted agents or immunotherapy in the KCSG HN15-16 TRIUMPH trial. Materials and Methods: We analyzed clinical characteristics and outcomes of patients with TP53 mutations in the TRIUMPH trial, a multicenter, biomarker-driven umbrella trial in Korea. Patients were assigned to treatment groups based on genomic profiles: group 1, alpelisib; group 2, poziotinib; group 3, nintedanib; and group 4, abemaciclib. If there was no identifiable target, the patients were allocated to group 5 (durvalumab±tremelimumab).

resultsTP53 mutations were detected in 116/179 patients (64.8%), more frequently in human papillomavirus-negative and non-oropharyngeal cancers. Patients with TP53 mutations exhibited shorter progression-free survival than TP53 wild-type in all the patients (1.7 vs. 3.8 months, p=0.002) and in those who received targeted treatments (2.5 vs. 7.3 months, p=0.009). Furthermore, TP53 mutations were strongly associated with poor overall survival than TP53 wild-type in all the patients (11.1 vs. 28.8 months, p=0.005) and in group 5 (8.1 vs. 33.0 months, p=0.001).

conclusionTP53 mutations were associated with aggressive clinical characteristics and poor survival, particularly in HNSCC patients treated with immunotherapy.

Indexed as

Head and Neck NeoplasmsImmunotherapyMutationSquamous Cell Carcinoma of Head and NeckTumor Suppressor Protein p53AdultAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedMolecular Targeted TherapyPrognosisBiomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53Head and neck neoplasmsImmunotherapyMolecular targeted therapyNext generation sequencingTumor suppressor protein P53

Identifiers

PMID39727015
PMCPMC12263242

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.